Browse IPO11

Summary
SymbolIPO11
Nameimportin 11
Aliases RanBP11; Ran binding protein 11; imp11; ran-binding protein 11; Importin-11
Chromosomal Location5q12.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cytoplasm Nucleus
Domain PF03810 Importin-beta N-terminal domain
Function

Functions in nuclear protein import as nuclear transport receptor. Serves as receptor for nuclear localization signals (NLS) in cargo substrates. Is thought to mediate docking of the importin/substrate complex to the nuclear pore complex (NPC) through binding to nucleoporin and the complex is subsequently translocated through the pore by an energy requiring, Ran-dependent mechanism. At the nucleoplasmic side of the NPC, Ran binds to the importin, the importin/substrate complex dissociates and importin is re-exported from the nucleus to the cytoplasm where GTP hydrolysis releases Ran. The directionality of nuclear import is thought to be conferred by an asymmetric distribution of the GTP- and GDP-bound forms of Ran between the cytoplasm and nucleus (By similarity). Mediates the nuclear import of UBE2E3, and of RPL12 (By similarity).

> Gene Ontology
 
Biological Process GO:0006606 protein import into nucleus
GO:0006610 ribosomal protein import into nucleus
GO:0006913 nucleocytoplasmic transport
GO:0017038 protein import
GO:0034504 protein localization to nucleus
GO:0042991 transcription factor import into nucleus
GO:0044744 protein targeting to nucleus
GO:0051169 nuclear transport
GO:0051170 nuclear import
GO:1902593 single-organism nuclear import
Molecular Function GO:0008536 Ran GTPase binding
GO:0008565 protein transporter activity
GO:0017016 Ras GTPase binding
GO:0031267 small GTPase binding
GO:0051020 GTPase binding
Cellular Component GO:0005635 nuclear envelope
> KEGG and Reactome Pathway
 
KEGG -
Reactome -
Summary
SymbolIPO11
Nameimportin 11
Aliases RanBP11; Ran binding protein 11; imp11; ran-binding protein 11; Importin-11
Chromosomal Location5q12.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between IPO11 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolIPO11
Nameimportin 11
Aliases RanBP11; Ran binding protein 11; imp11; ran-binding protein 11; Importin-11
Chromosomal Location5q12.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of IPO11 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NS NA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell logFC: -2.17; FDR: 0.04220 Resistant to T cell-mediated killing
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NS NA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NS NA/NS
24476824shRNAmelanomaB16Primary screen NA/NS NA/NS
24476824shRNAmelanomaB16Secondary screen NA/NS NA/NS
Summary
SymbolIPO11
Nameimportin 11
Aliases RanBP11; Ran binding protein 11; imp11; ran-binding protein 11; Importin-11
Chromosomal Location5q12.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of IPO11 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.3390.321
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)650.5560.626
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.1810.832
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.0780.814
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.5180.738
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.4790.808
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.0770.79
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.040.973
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.1460.91
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.2360.861
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 281.1820.537
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.0390.471
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of IPO11 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277311.11.49.70.0589
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275911.11.79.40.0895
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21174.804.81
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13117.707.71
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916012.5-12.50.52
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59022.2-22.20.505
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38275.305.30.507
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22139.109.10.519
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolIPO11
Nameimportin 11
Aliases RanBP11; Ran binding protein 11; imp11; ran-binding protein 11; Importin-11
Chromosomal Location5q12.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of IPO11. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolIPO11
Nameimportin 11
Aliases RanBP11; Ran binding protein 11; imp11; ran-binding protein 11; Importin-11
Chromosomal Location5q12.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of IPO11. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by IPO11.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolIPO11
Nameimportin 11
Aliases RanBP11; Ran binding protein 11; imp11; ran-binding protein 11; Importin-11
Chromosomal Location5q12.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of IPO11. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolIPO11
Nameimportin 11
Aliases RanBP11; Ran binding protein 11; imp11; ran-binding protein 11; Importin-11
Chromosomal Location5q12.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of IPO11 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolIPO11
Nameimportin 11
Aliases RanBP11; Ran binding protein 11; imp11; ran-binding protein 11; Importin-11
Chromosomal Location5q12.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between IPO11 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolIPO11
Nameimportin 11
Aliases RanBP11; Ran binding protein 11; imp11; ran-binding protein 11; Importin-11
Chromosomal Location5q12.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting IPO11 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.